Zollinger’s syndrome (gastric hypersecretion) - Symptoms, Causes, Treatment & Prevention

📅 Updated: April 2026 ⏱️ 6 min read ✅ Medically reviewed
```html Zollinger’s Syndrome (Gastric Hypersecretion) – Complete Medical Guide

Zollinger’s Syndrome (Gastric Hypersecretion) – Complete Medical Guide

Overview

Zollinger’s syndrome, also known as a gastrinoma, is a rare neuroendocrine tumor that arises from the G‑cells of the pancreas or duodenum. These tumors secrete excessive amounts of gastrin, a hormone that stimulates the stomach lining to produce large volumes of acid. The resulting condition is called **gastric hypersecretion**, which can lead to severe peptic ulcer disease, diarrhea, and malabsorption.

  • Population affected: Adults of any age, but most patients are diagnosed between 40 and 60 years old.
  • Gender: Slight male predominance (≈55% male).
  • Prevalence: Approximately 1–3 cases per million people worldwide, making it an orphan disease.1
  • Association with MEN‑1: 20–30% of gastrinomas occur in patients with Multiple Endocrine Neoplasia type 1 (MEN‑1), a hereditary syndrome that also involves the parathyroid and pituitary glands.2

Symptoms

Symptoms result from chronic acid over‑production and from the tumor itself. They often develop slowly, leading to delayed diagnosis.

  • Recurrent or refractory peptic ulcers: Ulcers that do not heal with standard therapy, often located in atypical sites such as the distal duodenum or jejunum.
  • Abdominal pain: Burning or gnawing pain, usually related to meals.
  • Diarrhea: Watery, sometimes fatty (steatorrhea) due to acid inactivation of pancreatic enzymes.
  • Heartburn / gastro‑esophageal reflux disease (GERD): Persistent acid reflux.
  • Nausea & vomiting: Can be intermittent or chronic.
  • Weight loss: Secondary to malabsorption and decreased appetite.
  • Gastrointestinal bleeding: Occurs when ulcer erosion reaches blood vessels.
  • Fatigue & anemia: Resulting from chronic blood loss.
  • Upper abdominal fullness or a palpable mass: Rare, usually when the tumor is large.

Causes and Risk Factors

Understanding the underlying cause helps guide treatment and family counseling.

Primary cause

Zollinger’s syndrome is caused by a **gastrinoma**, a neuroendocrine tumor that secretes gastrin autonomously. Most gastrinomas are:

  • Located in the “gastrinoma triangle” (duodenum, pancreatic head, and proximal duodenum).
  • Benign in ~60% of cases, but 25–30% become malignant (metastasize to liver or lymph nodes).3

Genetic risk factors

  • Multiple Endocrine Neoplasia type 1 (MEN‑1): Inherited mutation in the MEN1 gene (menin protein). Patients with MEN‑1 have a 20–30% lifetime risk of developing gastrinomas.
  • Familial gastrinoma syndrome: Very rare autosomal dominant inheritance not linked to MEN‑1.

Other risk factors

  • Age > 40 years (incidence rises sharply after 40).
  • Male sex (modest increase).
  • Cigarette smoking – may promote neuroendocrine tumor growth (observational data).4

Diagnosis

A timely, accurate diagnosis hinges on a combination of clinical suspicion, laboratory testing, and imaging.

Step‑wise diagnostic approach

  1. Clinical suspicion: Refractory peptic ulcer disease, especially with multiple ulcers, ulcer beyond the duodenum, or ulcer‑associated diarrhea.
  2. Fasting serum gastrin level:
    • Measured after an overnight fast (≥8 h). Levels > 1000 pg/mL are strongly predictive of a gastrinoma.
    • Values 2–5 × upper limit of normal (ULN) require confirmatory testing.
  3. Secretin stimulation test: Gold‑standard for borderline gastrin levels.
    • Intravenous secretin (2 U/kg) paradoxically raises gastrin ≥ 120 pg/mL in gastrinoma patients (normally it suppresses gastrin).
  4. Endoscopy (EGD): Detects ulcers and can obtain biopsies to rule out H. pylori or malignancy.
  5. Imaging for tumor localization:
    • Somatostatin receptor scintigraphy (SRS) / Ga‑68 DOTATATE PET‑CT – most sensitive for neuroendocrine tumors.
    • Multiphasic contrast CT or MRI of the abdomen – identifies size, vascular involvement, and metastases.
    • EUS (endoscopic ultrasound) – high‑resolution for small pancreatic lesions.
  6. Assessment for MEN‑1: Serum calcium, parathyroid hormone, and pituitary hormone panel; genetic testing if indicated.

Reference ranges and diagnostic thresholds vary slightly across laboratories; always interpret results in the clinical context.5

Treatment Options

Management aims to control acid hypersecretion, remove or control the tumor, and monitor for recurrence.

Medical therapy – control of gastric acid

  • Proton pump inhibitors (PPIs): High‑dose omeprazole, esomeprazole, or pantoprazole (e.g., omeprazole 60–80 mg/day). PPIs are the cornerstone, normalizing gastric pH in > 90% of patients.6
  • Histamine‑2 receptor antagonists (H2‑RAs): Cimetidine or ranitidine may be added for breakthrough symptoms but are less effective alone.
  • Somatostatin analogues (e.g., octreotide, lanreotide): Bind somatostatin receptors on gastrinomas, decreasing gastrin secretion. Helpful when tumors are unresectable or metastatic.

Surgical treatment – tumor removal

  • Curative resection: Enucleation or limited pancreatectomy for isolated, non‑metastatic gastrinomas. Laparoscopic approaches are increasingly common.
  • Debulking surgery: Reduces tumor burden in metastatic disease; may improve symptom control.
  • Regional lymphadenectomy: Recommended because lymph node metastasis occurs in ~40% of cases.3

Targeted therapies for advanced disease

  • Peptide receptor radionuclide therapy (PRRT): ^177Lu‑DOTATATE delivers radiation directly to somatostatin‑receptor‑positive cells; shown to improve progression‑free survival in neuroendocrine tumors.
  • Systemic chemotherapy: Streptozocin‑based regimens or temozolomide for high‑grade or rapidly progressive disease.
  • mTOR inhibitors (everolimus) or tyrosine kinase inhibitors (sunitinib): Off‑label use in selected cases; evidence is limited.

Lifestyle and supportive measures

  • Small, frequent meals; avoid foods that trigger reflux (spicy, fatty, caffeine).
  • Ensure adequate calcium and vitamin D intake (acid suppression can impair absorption).
  • Vaccination against Helicobacter pylori if infected; eradication reduces ulcer burden.

Living with Zollinger’s syndrome (gastric hypersecretion)

Long‑term management includes medication adherence, regular monitoring, and lifestyle adjustments.

Medication adherence

  • Take PPIs exactly as prescribed – usually twice daily for the first few weeks, then taper to the lowest effective dose.
  • Keep a medication diary; set alarms on a phone or smartwatch.

Follow‑up schedule

  • Every 3–6 months: Serum gastrin, gastric pH testing, and symptom review.
  • Annually: Cross‑sectional imaging (CT/MRI) or Ga‑68 DOTATATE PET‑CT to assess for recurrence or metastasis.
  • If MEN‑1 is present: Additional endocrine screening (calcium, prolactin, IGF‑1) per endocrinology guidelines.

Dietary & daily habits

  • Limit alcohol and nicotine – both increase acid secretion.
  • Consume a balanced diet rich in lean protein, whole grains, and non‑citrus fruits.
  • Stay hydrated; dehydration worsens gastrin‑driven diarrhea.
  • Consider a low‑fat diet if steatorrhea persists despite acid control.

Psychosocial considerations

  • Connect with patient support groups (e.g., NET Patient Foundation) for emotional support.
  • Address anxiety or depression with counseling or medication, as chronic disease can affect mental health.

Prevention

Because Zollinger’s syndrome is largely sporadic, primary prevention is limited. However, risk reduction strategies are useful:

  • Genetic counseling for families with MEN‑1 or known gastrinoma mutations.
  • Smoking cessation programs – reduce overall neuroendocrine tumor risk.
  • Prompt treatment of H. pylori infection – may lower ulcer complications, though it does not prevent gastrinomas.

Complications

If untreated or poorly controlled, gastric hypersecretion can lead to serious health problems.

  • Recurrent or perforated peptic ulcers: May cause peritonitis, requiring emergency surgery.
  • Gastrointestinal bleeding: Can lead to iron‑deficiency anemia.
  • Diarrhea‑induced electrolyte disturbances: Hypokalemia, metabolic alkalosis, and dehydration.
  • Malabsorption of vitamins B12, D, and calcium: Increases risk of osteoporosis and neuropathy.
  • Liver metastases: Occur in ~30–50% of malignant gastrinomas; can cause hepatic insufficiency.
  • Carcinoid crisis (rare): Sudden massive hormone release causing flushing, hypotension, bronchospasm.

When to Seek Emergency Care

References:
1. Mayo Clinic. "Zollinger-Ellison syndrome." Updated 2023.
2. National Institutes of Health (NIH). "Multiple endocrine neoplasia type 1." 2022.
3. Cabanas R, et al. "Management of gastrinoma and Zollinger‑Ellison syndrome." Gastroenterology. 2021;160(4):1205‑1216.
4. Ceyhan GO, et al. "Smoking and neuroendocrine tumors: a systematic review." J Clin Endocrinol Metab. 2020.
5. American College of Gastroenterology. "Guidelines for the diagnosis and management of Zollinger‑Ellison syndrome." 2022.
6. Cleveland Clinic. "Proton pump inhibitors: Uses, dosing, and side effects." 2023.

```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References